

# Hana M El Sahly

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7414802/publications.pdf>

Version: 2024-02-01

69  
papers

13,250  
citations

218381

26  
h-index

118652

62  
g-index

75  
all docs

75  
docs citations

75  
times ranked

20991  
citing authors

#	ARTICLE	IF	CITATIONS
1	Homologous and Heterologous Covid-19 Booster Vaccinations. <i>New England Journal of Medicine</i> , 2022, 386, 1046-1057.	13.9	418
2	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. <i>Science</i> , 2022, 375, 43-50.	6.0	788
3	SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination. <i>New England Journal of Medicine</i> , 2022, 386, 1088-1091.	13.9	338
4	Initial analysis of viral dynamics and circulating viral variants during the mRNA-1273 Phase 3 COVE trial. <i>Nature Medicine</i> , 2022, 28, 823-830.	15.2	26
5	Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 – a review. <i>Translational Research</i> , 2022, 242, 1-19.	2.2	3
6	A prospective cohort study of head circumference and its association with neurodevelopmental outcomes in infants and young children in rural Guatemala. <i>Journal of Developmental Origins of Health and Disease</i> , 2022, 13, 779-786.	0.7	2
7	Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial. <i>Journal of Infectious Diseases</i> , 2022, 226, 1731-1742.	1.9	8
8	Rapid decline in vaccine-boosted neutralizing antibodies against SARS-CoV-2 Omicron variant. <i>Cell Reports Medicine</i> , 2022, 3, 100679.	3.3	100
9	Durability of Protection Against Symptomatic COVID-19 Among Participants of the mRNA-1273 SARS-CoV-2 Vaccine Trial. <i>JAMA Network Open</i> , 2022, 5, e2215984.	2.8	3
10	Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 COVID-19 Vaccine Efficacy Clinical Trial. <i>Annals of Internal Medicine</i> , 2022, 175, 1258-1265.	2.0	63
11	Variability in the Management of Adults With Pulmonary Nontuberculous Mycobacterial Disease. <i>Clinical Infectious Diseases</i> , 2021, 72, 1127-1137.	2.9	23
12	Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 795-807.	13.9	1,398
13	Parent Report of Health Related Quality of Life in Young Children in Rural Guatemala: Implementation, Reliability, and Validity of the PedsQL in Stunting and Wasting. <i>Global Pediatric Health</i> , 2021, 8, 2333794X2199102.	0.3	1
14	Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. <i>New England Journal of Medicine</i> , 2021, 384, 403-416.	13.9	7,910
15	Immunogenicity and safety of different dose schedules and antigen doses of an MF59-adjuvanted H7N9 vaccine in healthy adults aged 65 years and older. <i>Vaccine</i> , 2021, 39, 1339-1348.	1.7	2
16	Topical Imiquimod Does Not Provide an Adjuvant Effect When Administered With Inactivated Influenza A/H5N1 Vaccine in Healthy Young Adults. <i>Journal of Infectious Diseases</i> , 2021, 224, 1712-1719.	1.9	5
17	Sensitive and Prolonged Detection of Dengue Virus RNA in Whole Blood. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 104, 1734-1736.	0.6	2
18	A Deferred-Vaccination Design to Assess Durability of COVID-19 Vaccine Effect After the Placebo Group Is Vaccinated. <i>Annals of Internal Medicine</i> , 2021, 174, 1118-1125.	2.0	15

#	ARTICLE	IF	CITATIONS
19	Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. <i>New England Journal of Medicine</i> , 2021, 385, 1774-1785.	13.9	402
20	Phase 3 Trial of mRNA-1273 during the Delta-Variant Surge. <i>New England Journal of Medicine</i> , 2021, 385, 2485-2487.	13.9	49
21	Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. <i>Science</i> , 2021, , eab3435.	6.0	145
22	CD8 Encephalitis in a Treatment-Naive and a Virologically Suppressed Patient with HIV – ERRATUM. <i>Canadian Journal of Neurological Sciences</i> , 2020, 47, 151-151.	0.3	1
23	Postacute COVID-19: An Overview and Approach to Classification. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa509.	0.4	128
24	An evaluation of cytokine and cellular immune responses to heterologous prime-boost vaccination with influenza A/H7N7-A/H7N9 inactivated vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 3138-3145.	1.4	4
25	Impact of the SARS-CoV-2 pandemic on health-care workers. <i>Hospital Practice (1995)</i> , 2020, 48, 161-164.	0.5	13
26	Reliability and Validity of an Adapted and Translated Version of the Mullen Scales of Early Learning (AT&MSEL) in Rural Guatemala. <i>Child: Care, Health and Development</i> , 2020, 46, 327-335.	0.8	13
27	757. Association between cumulative febrile, respiratory and diarrheal illness in the first year of life and neurodevelopmental and growth outcomes among a cohort of children in rural Guatemala. <i>Open Forum Infectious Diseases</i> , 2020, 7, S425-S426.	0.4	0
28	1407. Cytomegalovirus (CMV) infection in the first year of life in a cohort of infants in rural Guatemala. <i>Open Forum Infectious Diseases</i> , 2020, 7, S711-S712.	0.4	0
29	Receptive language skills among young children in rural Guatemala: The relationship between the Test de Vocabulario en Imagenes Peabody and a translated and adapted version of the Mullen Scales of Early Learning. <i>Child: Care, Health and Development</i> , 2019, 45, 702-708.	0.8	12
30	The Reply. <i>American Journal of Medicine</i> , 2019, 132, e668.	0.6	0
31	Occupational Exposure to the Ugandan Research Strain (MR766) of Zika Virus. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz420.	0.4	1
32	CD8 Encephalitis in a Treatment-Naive and a Virologically Suppressed Patient with HIV. <i>Canadian Journal of Neurological Sciences</i> , 2019, 46, 773-775.	0.3	7
33	Clinical, Virologic, and Immunologic Characteristics of Zika Virus Infection in a Cohort of US Patients: Prolonged RNA Detection in Whole Blood. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofy352.	0.4	26
34	Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination. <i>Vaccine</i> , 2019, 37, 2561-2568.	1.7	6
35	2801. Post-Natal Zika Virus Infection and Impact on Neurodevelopment Among a Cohort of Children in Rural Guatemala. <i>Open Forum Infectious Diseases</i> , 2019, 6, S990-S991.	0.4	0
36	846. Postnatally Acquired Zika Virus (ZIKV) Infection in Infants and Young Children in Guatemala: Serologic and Neurodevelopmental (ND) Evaluation. <i>Open Forum Infectious Diseases</i> , 2019, 6, S14-S15.	0.4	0

#	ARTICLE	IF	CITATIONS
37	Vaccination in the Adult Patient Infected with HIV: A Review of Vaccine Efficacy and Immunogenicity. <i>American Journal of Medicine</i> , 2019, 132, 437-446.	0.6	33
38	Responding to the Zika Epidemic: Preparation of a Neurodevelopmental Testing Protocol to Evaluate Young Children in Rural Guatemala. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 100, 438-444.	0.6	12
39	Optimizing PCR Detection of Zika Virus from Various Body Fluids. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 100, 427-433.	0.6	22
40	Randomized clinical trial of a single versus a double dose of 13-valent pneumococcal conjugate vaccine in adults 55 through 74 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine. <i>Vaccine</i> , 2018, 36, 606-614.	1.7	14
41	2492. Clinical, Virologic, and Immunologic Characteristics of Zika Virus Infection in a Cohort of US Patients. <i>Open Forum Infectious Diseases</i> , 2018, 5, S748-S748.	0.4	0
42	Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: A Phase 2 trial. <i>Vaccine</i> , 2017, 35, 923-928.	1.7	10
43	Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial. <i>Vaccine</i> , 2017, 35, 1675-1682.	1.7	17
44	Survival of an AIDS patient after infection with <i>Acanthamoeba</i> sp. of the central nervous system. <i>Infection</i> , 2017, 45, 715-718.	2.3	14
45	Tularemia vaccine: Safety, reactogenicity, skin reactions, and antibody responses following vaccination with a new lot of the <i>Francisella tularensis</i> live vaccine strain "A" A phase 2 randomized clinical Trial. <i>Vaccine</i> , 2017, 35, 4730-4737.	1.7	30
46	<i>Arcanobacterium haemolyticum</i> Central Nervous System Abscess and Bacteremia Following Head Trauma. <i>Infectious Diseases in Clinical Practice</i> , 2017, 25, e9-e11.	0.1	4
47	Humoral and Cell-Mediated Immune Responses to Alternate Booster Schedules of Anthrax Vaccine Adsorbed in Humans. <i>Vaccine Journal</i> , 2016, 23, 326-338.	3.2	9
48	<i>Mycobacterium avium</i> complex-associated cholecystitis in AIDS patient: a case description and review of literature. <i>International Journal of STD and AIDS</i> , 2016, 27, 1218-1222.	0.5	2
49	Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 237.	3.8	124
50	Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects. <i>Vaccine</i> , 2015, 33, 5225-5234.	1.7	92
51	Recombinant hemagglutinin protein vaccine: a new option in immunization against influenza. <i>Future Virology</i> , 2015, 10, 1057-1067.	0.9	2
52	Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations. <i>Vaccine</i> , 2015, 33, 163-173.	1.7	3
53	Performance of Xpert MTB/RIF in Induced Sputum Samples at Detecting <i>Mycobacterium Tuberculosis</i> . <i>Clinical Infectious Diseases</i> , 2014, 59, 911-912.	2.9	1
54	Immunogenicity and safety of four different dosing regimens of anthrax vaccine adsorbed for post-exposure prophylaxis for anthrax in adults. <i>Vaccine</i> , 2014, 32, 6284-6293.	1.7	10

#	ARTICLE	IF	CITATIONS
55	Effect of reduced dose schedules and intramuscular injection of anthrax vaccine adsorbed on immunological response and safety profile: A randomized trial. <i>Vaccine</i> , 2014, 32, 1019-1028.	1.7	32
56	Higher Antigen Content Improves the Immune Response to 2009 H1N1 Influenza Vaccine in HIV-Infected Adults: A Randomized Clinical Trial. <i>Journal of Infectious Diseases</i> , 2012, 205, 703-712.	1.9	26
57	Safety and immunogenicity of a candidate parvovirus B19 vaccine. <i>Vaccine</i> , 2011, 29, 7357-7363.	1.7	75
58	Incidence of Moxifloxacin Resistance in Clinical Mycobacterium tuberculosis Isolates in Houston, Texas. <i>Journal of Clinical Microbiology</i> , 2011, 49, 2942-2945.	1.8	15
59	MF59 <sup>®</sup> as a vaccine adjuvant: a review of safety and immunogenicity. <i>Expert Review of Vaccines</i> , 2010, 9, 1135-1141.	2.0	56
60	Pandemic H5N1 influenza vaccine development: an update. <i>Expert Review of Vaccines</i> , 2008, 7, 241-247.	2.0	44
61	Clinical data on Fluarix <sup>®</sup> : an inactivated split seasonal influenza vaccine. <i>Expert Review of Vaccines</i> , 2008, 7, 713-719.	2.0	5
62	Effects of a Reduced Dose Schedule and Intramuscular Administration of Anthrax Vaccine Adsorbed on Immunogenicity and Safety at 7 Months<sup>®</sup>; A Randomized Trial<sup>®</sup>. <i>JAMA - Journal of the American Medical Association</i> , 2008, 300, 1532.	3.8	90
63	Mortality associated with central nervous system tuberculosis. <i>Journal of Infection</i> , 2007, 55, 502-509.	1.7	40
64	Drug-resistant tuberculosis: A disease of target populations in Houston, Texas. <i>Journal of Infection</i> , 2006, 53, 5-11.	1.7	41
65	Safety and Immunogenicity of Nonadjuvanted and MF59-Adjuvanted Influenza A/H9N2 Vaccine Preparations. <i>Clinical Infectious Diseases</i> , 2006, 43, 1135-1142.	2.9	140
66	The effect of mannose binding lectin gene polymorphisms on susceptibility to tuberculosis in different ethnic groups. <i>Scandinavian Journal of Infectious Diseases</i> , 2004, 36, 106-108.	1.5	42
67	Mycobacterium simiae Pseudo-outbreak Resulting from a Contaminated Hospital Water Supply in Houston, Texas. <i>Clinical Infectious Diseases</i> , 2002, 35, 802-807.	2.9	73
68	Epidemiologic Differences between United States <sup>®</sup> and Foreign <sup>®</sup> Born Tuberculosis Patients in Houston, Texas. <i>Journal of Infectious Diseases</i> , 2001, 183, 461-468.	1.9	50
69	Unravelling the Treatment Effect of Baricitinib on Clinical Progression and Resource Utilization in Hospitalized COVID-19 Patients: Secondary Analysis of the Adaptive COVID-19 Treatment Randomized Trial-2. <i>Open Forum Infectious Diseases</i> , 0, , .	0.4	1